08048035996
VIVITRA 440MG Injection wholesale and global supplier from India to Australia | Phoenix Exim.

1. General Information

Vivitra 440mg Injection is an oncology medicine containing trastuzumab, a targeted biological therapy. It is designed for cancers in which tumor cells have increased levels of the HER2 (human epidermal growth factor receptor 2) protein. Treatment is selected after appropriate HER2 testing and is given under specialist medical supervision.

Product highlights:

  • Brand: Vivitra 440mg Injection
  • Active ingredient: Trastuzumab
  • Strength: 440 mg
  • Dosage form: Injection / infusion concentrate
  • Therapeutic category: Anticancer / targeted monoclonal antibody
  • Manufacturer reported for Vivitra: Zydus
  • Prescription medicine
  • Requires refrigerated storage and appropriate cold-chain handling.

2. Product Information

Vivitra 440mg is supplied as a trastuzumab-containing preparation for intravenous administration. The vial is prepared and diluted by healthcare professionals according to the approved product instructions before infusion.

The 440 mg strength is commonly used as part of trastuzumab treatment protocols, with the exact dose and schedule determined by the oncologist according to the cancer type, body weight, treatment regimen, and patient response.

3. Uses of Vivitra 440mg Injection

Vivitra 440mg Injection may be prescribed for:

  • HER2-positive breast cancer
  • HER2-positive metastatic breast cancer
  • HER2-positive gastric cancer
  • HER2-positive gastroesophageal-junction adenocarcinoma
  • Certain early-stage or advanced HER2-positive cancers, depending on the treatment protocol.

It may be used alone or alongside other anticancer medicines depending on the patient's clinical situation.

4. Benefits of This Medicine

The major benefit of trastuzumab is its targeted action against HER2. By binding to HER2 receptors, it can interfere with signals that encourage cancer-cell growth and survival. It can therefore help control the progression of appropriate HER2-positive cancers.

Potential treatment benefits include:

  • Targeted treatment for HER2-positive cancers
  • Helps slow cancer-cell growth
  • May help control disease progression
  • Can be incorporated into combination oncology treatment regimens
  • Provides a targeted alternative to less specific anticancer approaches in appropriate patients

Important: Benefits vary according to cancer stage, HER2 status, treatment combination, and individual patient response.

5. Side Effects of Vivitra 440mg Injection

Trastuzumab can cause side effects, and some can be serious. Important potential adverse effects include:

  • Infusion-related reactions
  • Allergic or hypersensitivity reactions
  • Heart problems, including reduced cardiac function or heart failure
  • Breathing or lung problems
  • Fever
  • Chills
  • Headache
  • Nausea
  • Diarrhea
  • Fatigue
  • Rash or other skin reactions
  • Infections

Serious breathing difficulty, severe allergic symptoms, or symptoms suggesting heart problems require urgent medical attention.

6. Common Side Effects

Some patients may experience:

  • Fever or chills
  • Headache
  • Weakness or tiredness
  • Nausea
  • Diarrhea
  • Cough
  • Rash
  • Muscle or joint discomfort
  • Infusion-related symptoms

Not everyone experiences these effects, and their severity can vary.

7. How to Use Vivitra 440mg Injection

Vivitra 440mg must not be self-administered.

A healthcare professional generally:

  1. Reconstitutes the vial according to the approved instructions.
  2. Dilutes the medicine appropriately.
  3. Administers it by intravenous infusion.
  4. Monitors the patient during and after administration, particularly for infusion reactions.
  5. Performs appropriate clinical monitoring throughout treatment.

The dosing interval may vary according to the prescribed oncology protocol. Do not determine the dose or infusion schedule yourself.

8. How This Medicine Works

Vivitra contains trastuzumab, a monoclonal antibody that specifically targets the HER2 receptor.

Some cancer cells produce excessive amounts of HER2, which can promote cancer-cell growth and survival. Trastuzumab binds to HER2 and interferes with these growth signals. It can also help the immune system recognize and attack HER2-positive cancer cells.

9. Safety Advice

  • Use only under the supervision of an oncologist or qualified healthcare professional.
  • HER2 testing should be performed before treatment when required.
  • Tell your doctor about any heart disease or previous heart problems.
  • Inform your doctor about breathing or lung problems.
  • Tell your healthcare team about all medicines, supplements, and cancer treatments you are receiving.
  • Heart function may need to be assessed before and during treatment.
  • Report severe infusion reactions immediately.
  • Seek urgent medical attention for severe breathing difficulty, swelling, severe allergic symptoms, or symptoms of heart failure.
  • Trastuzumab can cause fetal harm; patients who can become pregnant should discuss appropriate contraception and pregnancy precautions with their doctor.
  • Store the product according to the manufacturer's instructions; refrigerated/cold-chain handling is important and the product should not be frozen.

10. FAQs

Q1. What is Vivitra 440mg Injection?
Vivitra 440mg is a trastuzumab-containing targeted anticancer injection used for certain HER2-positive cancers.

Q2. What is the active ingredient in Vivitra 440mg?
The active ingredient is trastuzumab 440 mg.

Q3. What cancers can Vivitra 440mg treat?
It is used in appropriate patients with HER2-positive breast cancer and certain HER2-positive gastric or gastroesophageal-junction cancers.

Q4. Can Vivitra 440mg be self-injected?
No. It is administered intravenously by trained healthcare professionals.

Q5. Does Vivitra require refrigeration?
Yes. Appropriate refrigerated storage and cold-chain handling are required according to the product's storage instructions.

Q6. Is Vivitra suitable for every breast-cancer patient?
No. It is specifically intended for appropriate HER2-positive cases, based on medical evaluation and testing.

Q7. Can Vivitra affect the heart?
Yes. Trastuzumab can cause cardiac dysfunction in some patients, so appropriate heart-function monitoring is important.

Q8. Can Vivitra be used during pregnancy?
Trastuzumab may harm an unborn baby. Pregnancy-related precautions should be discussed with the treating physician before therapy.

11. Substitutes for Vivitra 440mg Injection

Because Vivitra contains trastuzumab, possible alternatives may include other trastuzumab products or other HER2-directed therapies, depending on the patient's diagnosis and treatment plan. The appropriate substitute cannot be selected solely on the basis of the brand name.

Examples of trastuzumab-containing products may include Herceptin and other approved trastuzumab biosimilars. The doctor should confirm the appropriate product, strength, formulation, and treatment regimen before substitution.

Do not switch oncology medicines without the prescribing oncologist's approval.

12. SEO Keywords

  • Vivitra 440mg Injection
  • Vivitra 440mg Injection exporter
  • Vivitra 440mg supplier from India
  • Vivitra 440mg Trastuzumab Injection
  • Trastuzumab 440mg Injection exporter India
  • Vivitra 440mg wholesale supplier
  • Vivitra 440mg pharmaceutical exporter
  • HER2 positive breast cancer injection
  • Trastuzumab injection supplier India
  • Vivitra 440mg oncology medicine exporter
  • Vivitra 440mg cancer treatment injection
  • Anti cancer injection exporter from India
  • Oncology medicine exporter Nagpur India
  • Trastuzumab 440mg global supplier
  • Vivitra 440mg international pharmaceutical supplier
  • Vivitra 440mg medicine exporter to USA
  • Vivitra 440mg exporter to UK
  • Vivitra 440mg exporter to Australia
  • Vivitra 440mg exporter to Singapore
  • Vivitra 440mg exporter to Canada
  • Vivitra 440mg exporter to South Korea
  • Vivitra 440mg exporter to UAE
  • HER2 targeted therapy supplier India
  • Trastuzumab oncology medicine wholesale
  • Vivitra 440mg pharmaceutical distribution
Aug 22nd, 2026 12:56 PM

Keywords